{
  "meta": {
    "title": "Iuds_Ocps",
    "url": "https://brainandscalpel.vercel.app/iuds-ocps-55541019.html",
    "scrapedAt": "2025-11-29T18:35:00.406Z"
  },
  "questions": [
    {
      "id": 2096,
      "choices": [
        {
          "id": 8375,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Terminate the pregnancy.</span></span></p>"
        },
        {
          "id": 8376,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Counsel her to continue the pregnancy as she had crossed the period of 24 weeks.</span></span></p>"
        },
        {
          "id": 87506,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Ask the husband if he wants to abort the child</span></span></p>"
        },
        {
          "id": 87507,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Start her on Methotrexate to avoid Ectopic pregnancy</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A pregnant woman at 28 weeks of gestation presents to your outpatient department with ultrasound findings indicating the presence of severe congenital anomalies in the fetus. She expresses significant distress and concern about the implications of these findings and the continuation of her pregnancy. As a medical officer, what is the most appropriate next step in managing this patient who presents with severe fetal congenital anomalies at 28 weeks of gestation?</span></span></p>",
      "unique_key": "Q5943657",
      "question_audio": null,
      "question_video": null,
      "map_id": 34413,
      "difficulty_level": "intermediate",
      "subjects_id": [
        7
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. A. Terminate the pregnancy</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A:</strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">In this specific case, since the patient is at <strong>28 weeks of gestation</strong> and considering that <strong>severe fetal congenital anomalies</strong> have been <strong>diagnosed</strong>, the <strong>law allows for the termination</strong> of <strong>pregnancy</strong> regardless of the <strong>gestational age</strong>. This is based on the <strong>clause that the length</strong> of <strong>pregnancy</strong> provisions does <strong>not apply</strong> in cases of <strong>substantial fetal abnormalities.</strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The decision to <strong>terminate the pregnancy</strong>, in this case, would typically involve a <strong>Medical Board&#39;s assessment</strong>, confirming the <strong>severity of the fetal anomalies</strong>. It is critical to have informed consent from the woman, respecting her autonomy and privacy in this decision-making process. The involvement of her partner in the discussion can be considered as supportive, but the ultimate decision rests with the woman.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>MTP (Amendment.</strong> <strong>Act, 2021)</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:14px\"><span style=\"font-family:Georgia,serif\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/07/20/image-20230720175451-1.png\" style=\"height:232px; width:750px\" /></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The <strong>Medical Termination of Pregnancy</strong> (Amendment<strong>.</strong> Act, 2021) provides for: </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Requirement of opinion of <strong>one</strong> registered medical practitioner for <strong>termination of pregnancy</strong> up to <strong>twenty weeks of gestation</strong>.</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Requirement of opinion of <strong>two </strong>registered medical practitioners for <strong>termination of pregnancy</strong> of <strong>twenty to twenty-four weeks of gestation.</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Enhancing the <strong>upper gestation limit</strong> from <strong>twenty to twenty-four weeks</strong> for <strong>vulnerable groups</strong> of <strong>women</strong> (such as minors, differently abled women, victims of violence etc.</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Non-applicability</strong> of the <strong>provisions relating to the length of pregnancy</strong> in cases where the termination of pregnancy is necessitated by the diagnosis of any of the<strong> substantial foetal abnormalities diagnosed by a Medical Board.</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Strengthening protection of privacy of a woman whose pregnancy has been terminated.</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Failure of contraceptive clause extended to woman and her partner. </span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation: </u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B.&nbsp;</strong><strong>Counsel her to continue the pregnancy as she had crossed the period of 24 weeks: </strong>&nbsp;Incorrect. The <strong>Medical Termination of Pregnancy</strong> (Amendment) <strong>Act, 2021</strong>, allows for <strong>termination beyond 24 weeks</strong> in cases of <strong>substantial fetal abnormalities</strong>. Thus, counseling to continue the pregnancy without considering termination may not be appropriate in this context, especially given the severity of the diagnosed anomalies.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C.&nbsp;Ask the husband if he wants to abort the child: </strong>&nbsp;Incorrect.&nbsp;The <strong>decision to terminate a pregnancy</strong> rests with the <strong>pregnant woman</strong>, and while the partner&#39;s support and opinion can be part of the discussion, it is the woman&#39;s consent that is legally and ethically paramount. </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D.&nbsp;Start her on Methotrexate to avoid Ectopic pregnancy: </strong>&nbsp;Incorrect and&nbsp;not relevant. <strong>Methotrexate</strong> is used in the <strong>medical management of ectopic pregnancy</strong>, not in the case of intrauterine pregnancy with fetal anomalies. Furthermore, Methotrexate is contraindicated in ongoing intrauterine pregnancies due to its teratogenic effects.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:center\"><span style=\"font-size:14px\"><span style=\"font-family:Georgia,serif\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/07/21/image_5zCvenF.png\" style=\"float:left; height:491px; width:800px\" /></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u>: RMNCAH+N guidelines, MoHFW.</strong></span></span></p>",
      "correct_choice_id": 8375,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 2185,
      "choices": [
        {
          "id": 8729,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Roll out of DMPA up to subcenter level</span></span></p>"
        },
        {
          "id": 8730,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Covers entire country</span></span></p>"
        },
        {
          "id": 8731,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Implementing new promotional schemes</span></span></p>"
        },
        {
          "id": 8732,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Creating an enabling environment</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">You are part of a public health team reviewing the progress of various health initiatives in your district, including the &quot;Mission Parivar Vikas&quot; program launched by the Ministry of Health and Family Welfare. A new member of the team is learning about the program and has some misconceptions. Which of the following statements about &quot;Mission Parivar Vikas&quot; is NOT true?</span></span></p>",
      "unique_key": "Q9411499",
      "question_audio": null,
      "question_video": null,
      "map_id": 34414,
      "difficulty_level": "intermediate",
      "subjects_id": [
        7
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans.&nbsp;B. Covers entire country.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">It <strong>does not</strong> cover the <strong>entire country</strong>, but rather <strong>focuses on specific areas</strong> with <strong>higher fertility rates.</strong> The aim is to <strong>increase access</strong> to <strong>contraceptives and family planning services</strong> in these <strong>selected districts to bring down fertility rates</strong> and <strong>improve maternal and child health outcomes.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Mission Parivar Vikas (MPV<strong>)</strong>&nbsp;was initially launched in <strong>146 high total fertility rate districts of 7 states </strong>to accelerate the use and awareness of family planning methods, later extended to <strong>cover entire districts of 7 high focus states.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Five-pronged strategy has been developed under the Mission Parivar Vikas:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Delivering assured services</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Building additional capacity/human resources development for enhanced service delivery</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Ensuring commodity security</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Implementing new promotional schemes</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Creating an enabling environment</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A. Roll out of DMPA up to subcenter level:</strong>&nbsp;<strong>Correct.</strong> One of the <strong>strategies of &quot;Mission Parivar Vikas</strong>&quot; includes the <strong>rollout of Depot Medroxyprogesterone Acetate</strong> (DMPA), a <strong>contraceptive injection</strong>, up to the subcenter level, enhancing access to long-acting reversible contraceptives.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C. Implementing new promotional schemes</strong>:&nbsp;<strong>Correct</strong>.&nbsp;<strong>Implementing new</strong> <strong>promotional schemes</strong> and <strong>incentives is part of the program&#39;s strategy</strong> to <strong>promote family planning</strong> and ensure wider outreach and acceptance within the target districts.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D. Creating an enabling environment:</strong>&nbsp;<strong>Correct</strong>,&nbsp;creating an <strong>enabling environment</strong> that <strong>supports family planning</strong> and the <strong>use of contraceptives</strong> is a <strong>key objective</strong> of the <strong>program.</strong> This includes community engagement, counseling services, and awareness campaigns.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Sterilization Incentive Package for MPV districts -&nbsp;</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/07/29/screenshot-2024-07-29-174027.png\" style=\"height:188px; width:1000px\" /></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>&nbsp;<u>Ref</u>: Park 26<sup>th</sup> ed pg. 595</strong></span></span></p>",
      "correct_choice_id": 8730,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 2195,
      "choices": [
        {
          "id": 8769,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">72 hours of unprotected intercourse</span></span></p>"
        },
        {
          "id": 8770,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">48 hours of unprotected intercourse</span></span></p>"
        },
        {
          "id": 8771,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">24 hours of unprotected intercourse</span></span></p>"
        },
        {
          "id": 8772,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">36 hours of unprotected intercourse</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 24-year-old woman presents to the clinic seeking advice on emergency contraception after an episode of unprotected intercourse 18 hours ago. She has no significant medical history and is not currently on any form of regular contraception. Within what timeframe should post-coital contraceptives be recommended?</span></span></p>",
      "unique_key": "Q5634591",
      "question_audio": null,
      "question_video": null,
      "map_id": 34415,
      "difficulty_level": "beginner",
      "subjects_id": [
        7
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. A. 72 hours of unprotected intercourse</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Post-coital</strong> or <strong>&ldquo;morning after&quot; contraception</strong> is recommended within <strong>72 hours of unprotected intercourse</strong>.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Emergency Contraception / Post-Coital Contraception / Intraception</strong> &ndash; It is the <strong>method of contraception</strong> which is <strong>employed within 72 hours of the intercourse</strong>. It includes &ndash;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ol style=\"list-style-type:lower-alpha\">\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>LNG</strong> &ndash; a single tablet of 1.5 mg or two tablets of 0.75 mg 12 hours apart should be given to prevent fertilization. It is the most commonly used method which is recommended by Government of India.</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ulipristal acetate</strong> &ndash; It is a SPRM, 30 mg tablet which can be used up to 5 days after intercourse.</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>CuT devices</strong> &ndash; These devices can be used within 5 days of the intercourse and is the most effective method.</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Mifepristone (RU 486) &ndash; </strong>It is a progesterone derivative which can be used to increase the thickness of secretions and make the endometrium out of phase to prevent implantation.</span></span></li>\r\n</ol>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Post-coital</strong> or <strong>&ldquo;morning after&quot; contraception</strong> is recommended within <strong>72 hours of unprotected intercourse.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref:</u> Park 26<sup>th</sup> ed, pg 581</strong></span></span></p>",
      "correct_choice_id": 8769,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}